Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Inhibrx Biosciences, Inc. (INBX)

Inhibrx posts updated corporate presentation with INBRX-106 HPV+ trial data

Neutral Impact 2 of 5 other Written later

Inhibrx Biosciences posted an updated corporate presentation to its website on September 28, 2026, and filed it as Exhibit 99.1 to this 8-K. The presentation shows early Phase 2 HexAgon-HN data for INBRX-106 combined with pembrolizumab, and it says a planned 50-patient expansion of the HPV-positive cohort may support a potential accelerated approval path by the end of 2028 or early 2029. The filing reports no new financial results, and the company states it has no obligation to update the materials.

Key points

  • HPV-positive cohort: confirmed objective response rate of 80.0% (8 of 10) with INBRX-106 plus pembrolizumab, versus 33.3% (3 of 9) with pembrolizumab alone, per the presentation.
  • Overall randomized population: objective response rate of 48.3% versus 26.5%, with a primary endpoint of cORR per the presentation; data cutoff August 19, 2026.
  • The company says it had $219.5 million in cash and cash equivalents and 14.7 million common shares outstanding as of August 6, 2026.
  • The presentation says the study amendment adds 50 HPV-positive patients, with potential accelerated approval by end of 2028 or early 2029.

The filing

CompanyInhibrx Biosciences, Inc. (INBX)
Form8-K, current report
Filed with the SECSep 28, 2026, 5:03 PM ET
Accession number0002007919-26-000050

Items reported: 7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 11:46 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on September 28, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.